We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+23.73%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.79B
AUM Growth
-$8.56B
Cap. Flow
-$9.86B
Cap. Flow %
-112.21%
Top 10 Hldgs %
80.97%
Holding
105
New
4
Increased
25
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$152M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.3M
3
RVMD icon
Revolution Medicines
RVMD
+$59M
4
REPL icon
Replimune Group
REPL
+$57.6M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$9.45B
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$337M
3
ONC
BeOne Medicines Ltd
ONC
+$199M
4
SWTX
SpringWorks Therapeutics
SWTX
+$69.4M
5
ROIV icon
Roivant Sciences
ROIV
+$41.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.37%
2 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
76
Whitehawk Therapeutics
WHWK
$181M
$508K 0.01%
251,727
-738,201
-75% -$3.1M
TARA icon
77
Protara Therapeutics
TARA
$213M
$374K ﹤0.01%
199,671
– –
CABA icon
78
Cabaletta Bio
CABA
$429M
$303K ﹤0.01%
13,331
-1,580,669
-99% -$26.6M
FHTX icon
79
Foghorn Therapeutics
FHTX
$278M
$290K ﹤0.01%
45,027
– –
BCEL
80
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$287K ﹤0.01%
2,177,499
-1,355,261
-38% -$318K
TYRA icon
81
Tyra Biosciences
TYRA
$1.82B
$147K ﹤0.01%
+10,607
New +$137K
SRZNW icon
82
Surrozen Inc Warrant
SRZNW
$36.6K
$16.2K ﹤0.01%
833,333
– –
AFMD
83
DELISTED
Affimed
AFMD
– –
-444,864
Closed -$2.13M
ALEC icon
84
Alector
ALEC
$169M
– –
-964,851
Closed -$6.25M
ANAB icon
85
AnaptysBio
ANAB
$1.53B
– –
-106,197
Closed -$1.91M
ARVN icon
86
Arvinas
ARVN
$525M
– –
-413,481
Closed -$8.12M
BLUE
87
DELISTED
bluebird bio
BLUE
– –
-124,986
Closed -$7.6M
BMRN icon
88
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-3,810,248
Closed -$337M
COGT icon
89
Cogent Biosciences
COGT
$6.69B
– –
-1,292,966
Closed -$12.6M
GERN icon
90
Geron
GERN
$911M
– –
-3,061,224
Closed -$6.49M
HRTX icon
91
Heron Therapeutics
HRTX
$92.5M
– –
-8,131,678
Closed -$8.38M
ITOS
92
DELISTED
iTeos Therapeutics
ITOS
– –
-150,346
Closed -$1.65M
NTRA icon
93
Natera
NTRA
$35.8B
– –
-100,000
Closed -$4.42M
PACB icon
94
Pacific Biosciences
PACB
$432M
– –
-1,127,782
Closed -$9.42M
RNAM
95
DELISTED
Avidity Biosciences
RNAM
– –
-166,347
Closed -$1.06M
SMMT icon
96
Summit Therapeutics
SMMT
$9.88B
– –
-3,140,473
Closed -$5.87M
SWTX
97
DELISTED
SpringWorks Therapeutics
SWTX
– –
-2,999,846
Closed -$69.4M
TIL icon
98
Instil Bio
TIL
$49.2M
– –
-235,220
Closed -$2.01M
VOR icon
99
Vor Biopharma
VOR
$1.08B
– –
-31,692
Closed -$1.34M
MORF
100
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-215,800
Closed -$4.94M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Baker Bros. Advisors held 105 positions worth $8.79B, down 49% from $17.4B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors withdrew a net $9.86B in Q4 2023, closing 21 positions and reducing 11 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $9.45B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock worth $67.8M.

  • Baker Bros. Advisors's largest Q4 2023 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 1,600,000 shares worth $67.8M.
  • Baker Bros. Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $152M increase.
  • Baker Bros. Advisors's biggest Q4 2023 reduction was BeOne Medicines Ltd, cutting an estimated $199M.
  • Baker Bros. Advisors fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $9.45B.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $8.79B portfolio in Q4 2023.
  • Baker Bros. Advisors opened 4 new positions and closed 21 in Q4 2023.
  • Baker Bros. Advisors's portfolio value fell 49% quarter-over-quarter to $8.79B.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.